The MHRA is consulting on making
Nuromol, a medicine that contains ibuprofen and paracetamol,
available without the need to visit a pharmacy.
Dr Sarah Branch, Director of Vigilance and Risk Management of
Medicines at the MHRA, said:
Every response received will help us gain a better picture of
whether people think Nuromol can be made available safely
without the need to visit a pharmacy.
We want to hear from as many people as possible, and therefore
we urge people to respond to our consultation and let us know
their views.
Nuromol is used for the temporary relief of mild to moderate pain
associated with migraine, headache, backache, period pain, dental
pain, rheumatic and muscular pain, pain of non-serious arthritis,
cold and flu symptoms, sore throat, and fever when paracetamol or
ibuprofen alone have not provided adequate pain relief. If
reclassified it will be available in a pack of 6 tablets.
While most people can take paracetamol, ibuprofen isn’t suitable
for everyone and it is important that people do not exceed the
recommended dose or take more than one paracetamol product at
once. We would like to hear from anyone who may be affected by
this proposed change in classification .
The MHRA welcomes views from the public and stakeholders on
whether this product should become a general sale medicine
(available in shops such as supermarkets as well as from
pharmacies). At present it is only available for purchase in
pharmacies, under the supervision of a pharmacist. The MHRA is
committed to making medicines easier to access, where it is safe
to do so. Therefore, it is vital that we hear what people have to
say on this consultation.
The Commission on Human Medicines advises the government on the
safety, quality and effectiveness of medicines and vaccines. They
have advised that it is safe for this product to potentially be
made available as a general sales product.
The Nuromol consultation is
open until 3 June 2021.
Notes to Editor
